The proposed objective of the UN Secretary General’s High-Level Panel (HLP) on Access to Medicines is to review and assess proposals and recommend solutions for remedying the policy incoherence between the rights of inventors, international human rights law, trade rules and public health in the context of health technologies. Four HLP Access to Medicines meetings were organized in Geneva, New York, London and Johannesburg.
DNDi submitted a formal contribution to the HLP on Access to Medicines. The Panel received approximately 170 submissions from many different public health organizations including; government agencies, international health organizations, universities, pharmaceutical companies and NGOs.
